本帖最后由 老马 于 2012-1-13 21:20 编辑
( F5 g. B {7 z) ?( O8 p, p' l- U% R7 c: s- o0 q6 E
爱必妥和阿瓦斯丁的比较
$ l* c4 {/ }5 J
/ _1 H0 v& g; e w) t; r
http://cancergrace.org/lung/2008/08/30/bms099-os-neg// b* \- k& Y: R, e9 {3 r
8 ~/ m4 c: A- `( `
" I g/ N0 B: o7 i# J# _ t
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# O; r4 }8 d F/ @1 S. r3 F==================================================2 W( ~# t* u! ]+ b- g( p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). r6 z0 z$ L# W+ I# \. O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point./ ?3 b( L% E ~9 Y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ H/ e- K$ I7 V9 R6 ?
|